Physician profile
Christopher Nobo
NPI 1407167919
$3,178.50
in general payments reported to CMS, 2019-2025
25 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $582 · 2021: $579 · 2022: $407 · 2023: $302 · 2024: $148 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $611.44 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $544.91 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $528.65 | 2019-2025 | Stelara, Tremfya |
| Olympus America INC. | $459.71 | 2019-2021 | |
| Vivus LLC | $127.58 | 2019-2023 | Pancreaze |
| Janssen Scientific Affairs, LLC | $120.96 | 2022 | |
| Boston Scientific Corporation | $105.82 | 2019-2021 | |
| Cook Medical LLC | $102.49 | 2021 | |
| Gilead Sciences, INC. | $97.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.02 | 2019-2022 | |
| Celgene Corporation | $81.60 | 2022-2023 | Zeposia |
| Evoke Pharma, INC. | $59.78 | 2022-2025 | Gimoti |
| Intercept Pharmaceuticals, INC. | $40.02 | 2020 | |
| Ironwood Pharmaceuticals, INC | $37.82 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $31.66 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.40 | 2025 | Wegovy |
| Lilly USA, LLC | $19.25 | 2025 | Zepbound |
| Alcresta Therapeutics, INC. | $18.20 | 2019 | |
| Genzyme Corporation | $17.31 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.24 | 2021 | |
| Qol Medical, LLC | $14.19 | 2025 | Sucraid |
| Ucb, INC. | $13.06 | 2019 | |
| Braintree Laboratories, INC. | $12.68 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.38 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nobo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.